-+ 0.00%
-+ 0.00%
-+ 0.00%

Veracyte TrueMRD test wins Medicare coverage for muscle-invasive bladder cancer monitoring

PUBT·05/15/2026 13:01:09
Listen to the news
Veracyte TrueMRD test wins Medicare coverage for muscle-invasive bladder cancer monitoring
  • Veracyte TrueMRD Monitoring Test won Medicare coverage under CMS MolDX for recurrence monitoring in muscle-invasive bladder cancer patients following curative-intent treatment.
  • Commercial launch scheduled for June 1, 2026, marking Veracyte first molecular residual disease offering.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260515626790) on May 15, 2026, and is solely responsible for the information contained therein.